Cellestia is a bio-pharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway.
cellestia biotech has raised €18M across 2 funding rounds from 2 investors, most recently a round in Aug 2021. Based in Lausanne, Switzerland; founded 2014; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2021-08-16 | Other | — | SNGLR Capital | View deal → |
| 2019-10-01 | Series B | €18M | FC Capital | View deal → |
